GlaxoSmithKline (GSK) has achieved topline results from seven of the eight Harmony Phase III studies investigating the use of albiglutide in patients with type 2 diabetes.
Go deeper with GlobalData
Albiglutide is an investigational biological injectable human glucagon-like peptide-1 (GLP-1) agonist that acts throughout the body to help maintain normal blood-sugar levels and control appetite.
The Phase III clinical development programme of albiglutide included eight individual studies, known as Harmony 1 to Harmony 8, evaluating the efficacy, tolerability and safety, including cardiovascular safety of the drug as mono and add-on therapy, in patients with type 2 diabetes.
The primary efficacy endpoint for all studies was the change from baseline in HbA1c compared to placebo and/or active comparators, including sulphonylurea, thiazolidinedione (TZD), insulin and a dipeptidyl peptidase four inhibitor (DPP IV).
See Also:
In Harmony 6, albiglutide produced considerable reductions in HbA1c from baseline and non-inferiority compared to preprandial lispro insulin after 26 weeks of treatment, achieving the primary endpoint.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe study showed a reduction in HbA1c from baseline of 0.82% for patients receiving albiglutide compared to a reduction of 0.66% for preprandial lispro insulin, while weight change from baseline was -0.73kg in the albiglutide arm and +0.81kg in the preprandial lispro insulin arm.
The head-to-head Harmony 7 study showed that patients receiving albiglutide demonstrated a reduction in HbA1c of 0.78% compared to a reduction of 0.99% for liraglutide, but it failed to meet the pre-specified primary endpoint of non-inferiority to liraglutide.
As well as the data from Harmony 6, 7 and 8 and the two-year data from the five ongoing studies, a meta-analysis of cardiovascular safety data will be required to complete the registration package as per the Food and Drug Administration guidelines.
The Harmony 8 study is scheduled for completion in mid 2012, and the remaining five studies are anticipated to be completed in early 2013.
Image: The current world headquarters of GlaxoSmithKline in Brentford, London. Photo: Maxwell Hamilton.
